View this email in your browser
CORNERSTONE AAV Process Development
It's all about safety and timelines! Therapeutic application of AAV-based gene therapy vectors requires consistent removal of host-cell contaminants and product related impurities, such as host cell DNA, proteins, their complexes and empty capsids.
CORNERSTONE AAV Process Development provides ideal solution. Includes unique CIMasphere™ extraction for early host cell-DNA and -protein management, strong CEX step to further disrupt complexes and finally successful E/F separation and elimination of residual DNA with strong AEX. To learn the basics of CORNERSTONE AAV Process click here.
Let us do the hard work for you - you will get your AAV DSP Process in time - we commit! For more information please contact us no matter how tough your timelines are! CORNERSTONE AAV Process Development is capable of managing even the most challenging projects!
BIA Separations announced as a finalist in category European CRO of the year
The purpose of annual European Lifestars Awards is recognising and celebrating the leading lights in life sciences. During the evening ceremony on November 19, 19 highly coveted awards will be presented. BIA Separations has been announced as a finalist in CRO category. Congratulations and good luck!
Featured Presentations Include:
  • Venkata Indurthi, Aldevron, USA
  • Andrew Knudten, Gene Therapy Consulting LLC, USA
  • Franz Gerner, RegenxBio, USA
  • Pete Gagnon, BIA Separations, Slovenia
...and many more. Download 2nd Announcement and discover what we have prepared!
Copyright © 2019 BIA Separations, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.